Add-on to 1-3 oral anti-hyperglycemic agents (metformin, sulfonylurea, or SGLT-2 inhibitor) SURPASS-4 (NCT03730662) was a 104-week open-label trial (52-week primary endpoint) that randomized 2002 adult patients with type 2 diabetes mellitus with increased cardiovascular risk to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin glargine 100 units/mL once daily (1:1:1:3 ratio) on a background of metformin (95%) and/or sulfonylureas (54%) and/or SGLT2 inhibitors (25%)
Illustration: L-Carnitine For Weight Loss: Diet And Workouts To Follow Discover the advantages and disadvantages of using l-carnitine for shedding fat
Legal and Regulatory Considerations In the United States, the regulatory status of BPC-157 is complex
How quickly will I notice results from B12 or Vitamin D injections
Formulated with performance-boosting vitamins, amino acids, and electrolytes, this powerful infusion fuels your body for intense workouts, enhances endurance, and sharpens focus
H.LimS.-Y.ChongK